AMP-activated Protein Kinase Inhibits the Glucose-activated Expression of Fatty Acid Synthase Gene in Rat Hepatocytes*

Marc ForetzDagger , David Carling§, Colette Guichard, Pascal Ferré, and Fabienne Foufelle

From the U465 INSERM, Centre Biomédical des Cordeliers, 15, rue de l'Ecole de Médecine, F-75270 Paris cedex 06, France and the § Molecular Medicine Group, Medical Research Council Clinical Sciences Center, Royal Postgraduate Medical School, Hammersmith Hospital, Ducane Road, London W12 0NN, United Kingdom

    ABSTRACT
Top
Abstract
Introduction
Procedures
Results & Discussion
References

Although it is now clearly established that a number of genes involved in glucose and lipid metabolism are up-regulated by high glucose concentrations in both liver and adipose tissue, the signaling pathway arising from glucose to the transcriptional machinery is still poorly understood. We have analyzed the regulation of fatty acid synthase gene expression by glucose in cultured rat hepatocytes. Glucose (25 mM) induces an activation of the transcription of the fatty acid synthase gene, and this effect is markedly reduced by incubation of the cells with okadaic acid, an inhibitor of protein phosphatases 1 and 2A. A similar reduction in glucose-activated fatty acid synthase gene expression is obtained by incubation with 5-amino-imidazolecarboxamide riboside, a cell-permeable activator of the AMP-activated protein kinase. Taken together, these results indicate that the glucose-induced expression of the fatty acid synthase gene involves a phosphorylation/dephosphorylation mechanism and suggest that the AMP-activated protein kinase plays an important role in this process. This is the first evidence that implicates the AMP-activated protein kinase in the regulation of gene expression. AMP-activated protein kinase is the mammalian analog of SNF1, a kinase involved in yeast in the transcriptional regulation of genes by glucose.

    INTRODUCTION
Top
Abstract
Introduction
Procedures
Results & Discussion
References

Although it is now clearly established that a number of genes involved in glucose and lipid metabolism are up-regulated by high glucose concentrations in both liver and adipose tissue (for review, see Refs. 1 and 2), the signaling pathway arising from glucose to the transcriptional machinery is still poorly understood. There is general agreement on the fact that glucose has to be metabolized to stimulate the transcription of lipogenic-related genes such as L-pyruvate kinase, fatty acid synthase (FAS),1 acetyl-CoA carboxylase (ACC), and S14 (3-5). In previous papers, we have proposed that glucose-6-phosphate could be the signal metabolite for the glucose-induced FAS transcription (3, 5, 6) and therefore for other genes belonging to the same class. This hypothesis was challenged by Doiron et al. (7) who proposed that the signal metabolite was xylulose-5-phosphate. However, whatever the metabolite, the link between the glucose signal and the activation of gene transcription remains unknown.

Phosphorylation/dephosphorylation processes are one of the major mechanisms involved in the regulation of glucose and lipid metabolism both at the cellular and molecular levels in eukaryotic cells. It is now well established that many transcription factors have their activity regulated by phosphorylation through a modification of their DNA binding activity, their transactivating capacity, or their subcellular localization (8).

In cultured hepatocytes, it has been shown that okadaic acid, an inhibitor of phosphatases 1 and 2A led to the inhibition of glucose stimulation of S14 gene transcription (9). Further experiments with calyculin, a much more potent inhibitor of protein phosphatase 1 than okadaic acid, suggest that protein phosphatase 2A may play the major role in the glucose effect. Finally, since the calcium ionophore A23187, an activator of Ca2+/calmodulin-dependent protein kinase (CaM kinase) inhibited the glucose effect, it was concluded that CaM kinase and protein phosphatase 2A were implicated in the glucose regulation of S14 gene transcription (9).

In the present work, we show that AMP-activated protein kinase (AMPK) is involved in the regulation by glucose of FAS gene expression in cultured hepatocytes. It must be pointed out that AMPK is the mammalian equivalent of SNF1, a protein kinase complex essential for glucose-regulated gene expression in yeast through the modulation of the transcriptional activity of nuclear factors.

    EXPERIMENTAL PROCEDURES
Top
Abstract
Introduction
Procedures
Results & Discussion
References

Animals-- Animal studies were conducted according to the French Guidelines for the Care and Use of Experimental Animals. Female Wistar rats (200-300 g body weight) from Iffa-Credo, (L'Arbresle, France) were used. They were housed in plastic cages at a constant temperature (22 °C) with light from 0700 h to 1900 h for at least one week before the experiments.

Isolation and Primary Culture of Hepatocytes-- Hepatocytes were isolated by the collagenase method (10). Cell viability was assessed by the Trypan Blue exclusion test and was always higher than 85%. Hepatocytes were seeded at a density of 8 × 106 cells/dish in 100-mm Petri dishes in medium M199 with Earle's salts (Life Technologies, Inc., Paisley, UK) supplemented with 100 units/ml penicillin, 100 µg/ml streptomycin, 0.1% (w/v) bovine serum albumin, 2% (v/v) Ultroser G (IBF, Villeneuve la Garenne, France), 100 nM dexamethasone (Sigma), 1 nM insulin (Actrapid, Novo-Nordisk, Copenhagen, Denmark), 100 nM triiodothyronine (T3) (Sigma). After cell attachment (4 h), the hepatocytes were cultured for 16-18 h in the presence of 5 mM glucose in a medium similar to the seeding medium but free of Ultroser and albumin and containing 100 nM insulin. The presence of dexamethasone, T3, and insulin in the culture medium ensures a maximal activity of glucokinase, necessary for a full glucose effect on FAS gene expression (11, 12). After 16-18 h, the culture medium was removed and hepatocytes were then cultured for 1, 3, or 6 h in the presence of either 5 or 25 mM glucose, hormones, and various compounds including 10-100 nM okadaic acid (Sigma), 50 µM H7 (protein kinase A and C inhibitor) (Sigma), 1 µM A23187 (activator of CaM kinases) (Sigma), 1 µM KN62 (inhibitor of CaM kinase II) (Sigma), 50-500 µM 5-aminoimidazole-4-carboxamide-1-beta -D-ribofuranosyl (AICAR) (Sigma) (activator of AMPK).

Metabolite Concentration Assay-- Cells were scrapped into 0.5 ml of 6% (v/v) ice-cold HClO4 in less than 5 s after removing the culture medium. The concentrations of metabolites including glucose-6-phosphate, lactate, AMP, ADP, and ATP were assayed enzymatically as described previously (13).

Measurement of AMPK Activity-- Hepatocytes were directly lyzed in the culture medium by adding 1.5 ml of buffer A (final concentrations of 50 mM Tris-HCl, pH 7.5, 50 mM NaF, 5 mM sodium pyrophosphate, 1 mM EDTA, 10% glycerol, 1 mM dithiothreitol) + 1% Triton X-100. The cellular debris were pelleted by centrifugation at 4000 × g for 15 min, and the resulting supernatant was removed, adjusted to 10% with PEG 6000 (Appligene, Illkirch, France), and kept on ice for 20 min. Following further centrifugation (7000 × g, 15 min), the pellet of proteins was resuspended in 400 µl of buffer A. Aliquots (5 µl) were used to assay the AMPK activity by the SAMS peptide phosphorylation assay in the presence of saturating concentrations of 5'-AMP (200 µM) as described previously (14).

Purification of AMPK-- AMPK was partially purified from rat liver up to and including the DEAE-Sepharose ion-exchange step as described previously (15). AMPK was further purified by immunoprecipitation using antibodies raised against the AMPKbeta 1 subunit bound to protein A-Sepharose. The immune complex was washed thoroughly with buffer A, and the resin was suspended in buffer A as a 50% (v/v) slurry and used for phosphorylation reactions.

Isolation of Total RNA and Northern Blot Hybridization-- Total cellular RNAs were extracted from hepatocytes using the guanidine thiocyanate method (16) and prepared for Northern blot hybridization as described previously (17). Labeling of each probe was performed by random priming (Rediprime labeling kit, Amersham Pharmacia Biotech). Autoradiograms of Northern blots were scanned and quantified using an image processor program.

FAS and PEPCK cDNAs were as described previously (17). Albumin, beta -actin, and glucokinase cDNA were gifts of kindness, respectively, from Drs. J. L. Danan (Meudon, France), B. Spiegelman (Boston, MA), and P. Ineydjian (Geneva, Switzerland). Each Northern blot was hybridized with a ribosomal 18 S cDNA to verify that equivalent amounts of total RNA were loaded in each lane.

Nuclear Run-on Transcription Assay-- Nuclei isolation and nuclear run-on transcription experiments were performed as described by Dugail et al. (18).

Statistical Analysis-- Results are expressed as means ± S.E. Statistical analysis was performed with Student's t test for unpaired data. When quantified, FAS mRNA concentrations were normalized with respect to the 18 S hybridization signal.

    RESULTS AND DISCUSSION
Top
Abstract
Introduction
Procedures
Results & Discussion
References

Okadaic Acid Inhibits the Glucose Effect on FAS Gene Expression-- To investigate whether a phosphorylation/dephosphorylation mechanism is involved in the glucose signaling pathway, we have used okadaic acid, a potent inhibitor of type 1 and 2A protein phosphatases (19), the most abundant phosphatases present in the liver (20). Okadaic acid has been shown to increase the phosphorylation state of a number of proteins including ACC or L-PK in rat hepatocytes, leading to increased glucose output and reduced glycolysis and lipogenesis (20). A major problem faced by studies using okadaic acid in whole cells is that, due to the widespread role of protein phosphorylation, long-term incubations could lead to secondary effects not related to glucose signaling. To minimize this problem in the present study, okadaic acid was added at the same time as 25 mM glucose in cultured hepatocytes, and FAS mRNA concentration measurements were performed after only 3 h. Okadaic acid at a dose of 10 nM decreases glucose-induced FAS expression by 50%, with a maximal effect obtained at 50 nM (Fig. 1). Moreover, the inhibitory effect of okadaic acid is not due to a general impairment of transcription mechanisms since (i) the expression of a control gene, beta -actin, is not affected in the same experiments (Fig. 1), and (ii) the inhibitory effect of okadaic acid on PEPCK mRNA abundance in hepatocytes, a phenomenon previously described (21), can still be counteracted by glucagon (Fig. 1).


View larger version (52K):
[in this window]
[in a new window]
 
Fig. 1.   Effect of okadaic acid on glucose-induced FAS gene expression in cultured hepatocytes. Top panel, hepatocytes were cultured for 16-18 h in the presence of 5 mM glucose and hormones (100 nM insulin, 100 nM dexamethasone, 100 nM T3). Cells were then treated for 3 h with 25 mM glucose and hormones in the absence or in the presence of increasing concentrations of okadaic acid (10-100 nM). Control hepatocytes were cultured with a non-inducible concentration of glucose (5 mM). Bottom panel, hepatocytes were cultured for 16-18 h in the presence of 5 mM glucose. Cells were then treated for 3 h with 100 nM okadaic acid in the absence or in the presence of 1 µM glucagon. The Northern blots presented are representative of three different culture experiments.

Previous studies have shown that glucose metabolism is a prerequisite for glucose action on FAS gene expression (3, 5). It was important, therefore, to ensure that in these experiments, okadaic acid did not directly affect glucose metabolism. In fact, glucose-6-phosphate concentrations measured 1 h after 10 nM okadaic acid addition, a dose which markedly inhibits FAS gene expression, were rather slightly increased (control, 2.20 ± 0.14 nmol/106 hepatocytes (n = 3); okadaic acid-treated, 2.76 ± 0.13 nmol/106 hepatocytes (n = 3)). Furthermore, lactate produced from glucose in the culture medium 3 h after 10 nM okadaic acid addition was unchanged (control, 1.50 ± 0.02 µmol/106 hepatocytes (n = 3); okadaic acid-treated, 1.48 ± 0.1 µmol/106 hepatocytes (n = 3)). These data rule out an indirect effect of okadaic acid through an impairment of glucose metabolism.

Our results are reminiscent of experiments showing that S14 gene transcription in cultured hepatocytes is inhibited by incubation with 5 nM okadaic acid with a maximal effect at 50 nM (9). Due to the fact that okadaic acid is not selective between phosphatases 1 and 2A, we cannot conclude whether phosphatase 2A alone is involved as shown for glucose induction of S14 gene transcription (9). Nevertheless, these experiments demonstrate that the stimulatory effect of glucose on FAS gene expression does involve a dephosphorylation mechanism.

An Activator of AMPK Opposes the Glucose Effect on FAS Gene Expression-- Having established that protein phosphatases are involved in the glucose signaling pathway, we next investigated which protein kinases were involved. Cultured hepatocytes were incubated in the presence of a number of different compounds to modulate the activity of various protein kinases (see "Experimental Procedures"). In all cases, except when Bt2cAMP was used, hepatocytes were incubated with a sub-maximal concentration of glucose (15 mM) to be able to detect both an increase or decrease in FAS gene expression by the various drugs.

We have analyzed the effects of H7, an inhibitor of both cAMP-dependent protein kinase (PKA) and protein kinase C (22), A23187, a calcium ionophore that activates CaM kinases (23) and KN62, a specific inhibitor of CaM kinase II (24). In the presence of these various compounds (Fig. 2, top and middle panels), there was no significant change in the glucose-induced FAS gene expression. In contrast, AICAR, a compound which has been shown to activate AMPK in a number of cell types, including primary rat adipocytes and hepatocytes (14, 25) and Bt2cAMP (an activator of PKA), strongly reduces the stimulating effect of glucose on FAS gene expression (Fig. 2, middle and bottom panels). The inhibitory effect of AICAR is not a general effect on gene transcription as shown by the fact that glucokinase gene expression is not modified by the compound (Fig. 2, middle panel). Similarly, the inhibitory effect of cAMP on FAS gene expression was specific since PEPCK gene expression was strongly stimulated by Bt2cAMP (Fig. 2, bottom panel). These results suggest a potential involvement of AMPK and PKA in the glucose signaling pathway.


View larger version (62K):
[in this window]
[in a new window]
 
Fig. 2.   Effect of kinase activators and inhibitors on glucose-induced FAS gene expression in cultured hepatocytes. Hepatocytes were cultured for 16-18 h in the presence of 5 mM glucose and hormones (100 nM insulin, 100 nM dexamethasone, 100 nM T3). Top panel, cells were then treated for 6 h with 15 or 25 mM glucose and hormones in the absence or in the presence of different inhibitors and activators of kinases: 50 µM H7, an activator of both kinases A and C; 1 µM A23187, an activator of CaM kinases; and 1 µM KN62, an inhibitor of CaM kinase II. Middle panel, cells were then treated for 6 h with 15 or 25 mM glucose and hormones in the absence or in the presence of different inhibitors and activators of kinases: 1 µM A23187; 50 µM H7; and 500 µM AICAR, an activator of AMP-activated protein kinase. Bottom panel, cells were then treated for 6 h with 25 mM glucose and hormones in the absence or in the presence of 100 µM Bt2cAMP. Total RNA were extracted and analyzed for the concentration of FAS, glucokinase, and PEPCK mRNAs. Loading of equivalent amounts of total RNA was checked by hybridization with a ribosomal 18 S cDNA probe. These Northern blots are representative of three different culture experiments.

We have already shown that activation of PKA in adipose tissue counteracted the glucose effect on FAS gene expression (26). Similarly, activation of PKA inhibited glucose-induced expression of the S14 (27) and L-PK (28) genes, although for the former, it has been attributed to an effect on glucose metabolism (9) and for the latter to an effect on glucokinase activity. Indeed, the cAMP inhibitory effect on L-PK gene expression was lost in a hepatoma cell line expressing hexokinase II rather than glucokinase (29). In the present study, Bt2cAMP strongly increases glucose-6-phosphate concentration in hepatocytes (result not shown), ruling out an indirect metabolic effect of PKA activation. If PKA was the kinase partner of the glucose signaling system, it would be anticipated that its inactivation should stimulate the FAS gene expression in the presence of 15 mM glucose. Since an inhibitor of PKA (H7) has no stimulatory effect on FAS gene expression (Fig. 2), this may indicate that PKA inhibits FAS gene expression by a mechanism that is unrelated to the glucose activating system. Moreover, in hepatocytes cultured in the presence of 5 mM glucose which express FAS at a low level, cAMP concentration should be already low due to the presence of insulin. This is backed up by the observation that PEPCK gene expression, which is dependent upon the activation of PKA, is barely detectable in these culture conditions (results not shown). This strongly suggests that PKA is not involved in the inhibition of FAS gene expression at low glucose concentrations. This hypothesis is consistent with the finding that a cAMP DNA response element has been localized at -99 to -92 in the FAS promoter (30), a region which bears no relationship with known glucose-response elements (for review, see Ref. 1).

Following uptake into the cell, AICAR is metabolized into ZMP, a relatively potent activator of AMPK (14, 25, 31). Progressive inhibition of glucose-induced FAS gene expression by increasing concentrations of AICAR was indeed paralleled by an increased activity of AMPK (Fig. 3). In the same culture experiments, glucokinase gene expression that is not controlled by glucose but by insulin (32) was not affected (Fig. 3). Activation of AMPK in the presence of 15 mM glucose and 500 µM AICAR did not affect glucose-6-phosphate concentrations measured 1 h after the addition of the drug (control, 1.40 ± 0.22 nmol/106 hepatocytes (n = 6); AICAR-treated, 1.18 ± 0.14 nmol/106 hepatocytes (n = 6) (difference not significant)). Finally, in the presence of a submaximally effective dose of AICAR, glucose could still stimulate FAS gene expression although with a much lower efficiency (Fig. 4).


View larger version (32K):
[in this window]
[in a new window]
 
Fig. 3.   Effect of increasing concentrations of AICAR on glucose-induced FAS gene expression and AMPK activity. Hepatocytes were cultured for 16-18 h in the presence of 5 mM glucose and hormones (100 nM insulin, 100 nM dexamethasone, 100 nM T3). Cells were then treated for 6 h with 25 mM glucose and hormones in the absence or in the presence of increasing concentrations of AICAR (50-500 µM) and then sampled either for mRNA extraction or for AMPK activity measurement. Top panel, total RNA were extracted and analyzed for expression of FAS and glucokinase genes. A representative Northern blot from two experiments is shown. Bottom panel, AMPK activity expressed in cpm incorporated into SAMS peptide/min/µg of protein. The results are presented as the mean ± S.E. for two experiments with triplicates in each experiment.


View larger version (32K):
[in this window]
[in a new window]
 
Fig. 4.   Effect of glucose on FAS gene expression in the presence of a submaximal dose of AICAR in cultured hepatocytes. Hepatocytes were cultured for 16-18 h in the presence of 5 mM glucose and hormones (100 nM insulin, 100 nM dexamethasone, 100 nM T3). Cells were then treated for 6 h with increasing concentrations of glucose (15-35 mM) in the absence or in the presence of 200 µM AICAR. The results are presented as a representative Northern blot (top panel) or in arbitrary densitometric units as the mean of two experiments with duplicates in each experiments (bottom panel).

Activation of AMPK Decreases Glucose-induced FAS Gene Expression by a Transcriptional Mechanism-- To assess whether the decreased expression of FAS gene by the activation of AMPK was due to a transcriptional and/or a post-transcriptional mechanism, run-on experiments were performed. Nuclei were isolated from hepatocytes cultured for 1 h in the presence of 5 or 25 mM glucose and in the absence or presence of AICAR (250 µM). Glucose at the high concentration clearly increases FAS gene transcription (Fig. 5). This increase was strongly (but not totally) repressed in the presence of AICAR, whereas glucokinase transcription was neither affected by glucose nor by AICAR (Fig. 5). It is therefore clear that the decreased FAS gene expression when AMPK is activated involves a transcriptional mechanism. Nevertheless, since the inhibitory effect of AICAR on FAS gene transcription is not total whereas the effect on FAS mRNA concentration is drastic, this might indicate an effect of AMPK activation on FAS mRNA half-life. On the other hand, the partial inhibitory effect of AICAR on FAS gene transcription might suggest that other kinases are also involved in the glucose-signaling system.


View larger version (34K):
[in this window]
[in a new window]
 
Fig. 5.   Effect of glucose and AICAR on FAS and glucokinase gene transcription in cultured hepatocytes. Hepatocytes were cultured for 16-18 h in the presence of 5 mM glucose and hormones (100 nM insulin, 100 nM dexamethasone, 100 nM T3). Cells were then treated for 1 h with 5 or 25 mM glucose and hormones in the absence or in the presence of 250 µM AICAR. Nuclei were isolated from cultured cells as described under "Experimental Procedures." The radiolabeled transcripts were hybridized to dot-blotted cDNAs for FAS, glucokinase, and to pBluescript II KS+, the vector into which the inserts were cloned. The blot is representative of two experiments.

The bulk of these studies strongly suggests that AMPK interferes with the glucose-signaling system for the FAS gene transcription. In addition to our findings, there are a number of features that provide clues for a role of AMPK in gene regulation in response to glucose. First, AMPK phosphorylates and inactivates ACC and 3-hydroxy-3-methylglutaryl-CoA reductase, resulting in the inhibition of both lipogenesis and cholesterol synthesis (33). These two pathways utilize acetyl-CoA as a substrate that, for a large part, originates from glucose. The action of AMPK on FAS gene expression would thus allow the potential for the coordinate regulation of lipid synthesis from glucose in both the short and long term. Second, and perhaps most interesting, is the finding that AMPK is structurally and functionally related to the yeast SNF1 protein kinase complex (34). AMPK consists of three subunits, a catalytic subunit, alpha  (63 kDa), and two noncatalytic subunits, beta  (30 kDa) and gamma  (36 kDa). AMPK alpha  subunit is 46% identical to yeast Snf1p, and this similarity increases to 60% within the kinase catalytic domains (35, 36). The gamma  subunit is 35% identical to yeast Snf4p (37), which is required for the protein kinase activity of Snf1p, just as the mammalian gamma  subunit is essential for the maximal kinase activity of the catalytic alpha  subunit (38). The AMPK beta  subunit is related to the yeast Sip family which interacts with Snf1p (37). Studies using synthetic peptides as substrates have revealed that both AMPK and SNF1 share very similar recognition motifs for phosphorylation, and moreover, they both phosphorylate and inactivate acetyl-CoA carboxylase in vivo (35). Most importantly, the activity of SNF1 is essential for the transcriptional activation of glucose-repressed genes in Saccharomyces cerevisiae (39). This is achieved through the phosphorylation of a transcription factor, depending upon the medium glucose concentration (40). Finally, it can be underlined that, as described for the glucose control of gene expression in mammals, the phosphorylation of glucose by a hexokinase is an essential step for the transcriptional effect of glucose in yeast (41). It is then tempting to speculate that the general mechanisms involved in the regulation of gene expression by glucose in mammals bear similarity with those described in yeast.

Glucose and Its Signal Metabolite Do Not Modulate the Concentration of AMP or the Activity of AMPK-- It has been suggested that SNF1 activity varies in response to glucose in yeast (35). One obvious possibility was that a high glucose concentration decreases the activity of AMPK. AMP activates AMPK through several independent mechanisms: allosteric activation of AMPK, stimulation of an AMPK kinase (AMPK is activated by phosphorylation), and inhibition of the deactivation of AMPK by PP-2C (42). A decreased AMPK activity in the presence of a high glucose concentration could be achieved (i) by decreasing the concentration of AMP, (ii) by altering the phosphorylation state of the enzyme, or (iii) by a direct allosteric interaction between the glucose signal metabolite and AMPK.

To test the first hypothesis, we have measured the concentration of AMP in the presence of 5 or 25 mM glucose. As can be seen from Table I, a high glucose concentration does not modify AMP, ADP, or ATP concentrations.

                              
View this table:
[in this window]
[in a new window]
 
Table I
AMPK activity and ATP, ADP, and AMP concentrations in cultured hepatocytes in the presence of 5 and 25 mM glucose and AICAR
Hepatocytes were cultured for 16-18 h in the presence of 5 mM glucose and hormones (100 nM insulin, 100 nM dexamethasone, 100 nM T3). Cells were then treated for 1 h with 5 or 25 mM glucose and hormones in the absence or in the presence of 500 µM AICAR. AMPK activity is expressed as cpm incorporated into SAMS peptide/min/µg of protein. Results are presented as mean ± S.E. for three experiments. *, Difference significant for p < 0.001 when compared with hepatocytes cultured in the presence of 25 mM glucose alone.

We have then assessed whether AMPK activity, and hence its phosphorylation state, was modified in the presence of a stimulating glucose concentration in cultured hepatocytes. This measurement relies on the fact that a change in the phosphorylation state of AMPK in the hepatocyte would be preserved in our assay conditions because of the presence of phosphatase inhibitors. As summarized in Table I, a high glucose concentration had no inhibitory effect on AMPK activity, whereas AICAR clearly increases its activity.

A last possibility was that the glucose signal metabolite could modify AMPK activity. An antagonism between glucose-6-P and AMP on AMPK activity was not unlikely since it has already been described for mammalian glycogen phosphorylase (43). We measured the activity of purified AMPK in the presence and absence of AMP and in the presence of increasing concentrations (from 0 to 500 µM) of glucose-6-phosphate. AMPK activity was not modified by this sugar phosphate (results not shown).

These experiments suggest that the glucose signal does not modify AMPK activity directly, at least in our assay system. It must be pointed out, however, that in contrast with yeasts, the switch from a high to a low glucose medium concentration in hepatocytes is not concomitant with a large decrease in the energy charge (AMP to ATP ratio). It is possible that the effect of glucose on AMPK is indirect and is mediated by decreasing the phosphorylation state of specific downstream targets of AMPK. This could occur either through the direct stimulation of a protein phosphatase or by rendering the target protein a better substrate for dephosphorylation. A similar mechanism involving glucose-6-phosphate has been described already for the dephosphorylation and activation of glycogen synthase in hepatocytes (44).

General Conclusion-- The main stimulator of FAS gene expression in adipose tissue and in the liver is glucose with insulin having an indirect effect (3, 5). We have shown presently that phosphorylation/dephosphorylation mechanisms are involved in the control of FAS gene expression by glucose. AMPK could be among the kinases involved in this regulation. The mechanisms by which glucose and its signal metabolite modulate the system do not involve a change in AMPK activity itself but more probably the phosphorylation state of a downstream target of the kinase. Although it is well established that PKA directly modulates the transcriptional activity of nuclear factors (45), it is not possible to conclude from the present study whether that is also the case for AMPK, and this must await the clear identification of the transcription factors involved in the glucose response.

    FOOTNOTES

* This work was supported in part by Grant 96/3011 from the European Economic Community Fair Program.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger Recipient of a doctoral fellowship from the Ministère de l'Enseignement Supérieur et de la Recherche.

Supported by the CNRS and to whom correspondence should be addressed. Tel.: 33-1-42-34-6922; Fax: 33-1-40-51-8586; E-mail: pferre{at}planete.net.

1 The abbreviations used are: FAS, fatty acid synthase; ACC, acetyl-CoA carboxylase; AICAR, 5-aminoimidazole-4-carboxamide-1-beta -D-ribofuranosyl; AMPK, AMP-activated protein kinase; CaM kinase, Ca2+/calmodulin-dependent kinase; L-PK, L-pyruvate kinase; PEPCK, phosphoenolpyruvate carboxykinase; PKA, protein kinase cAMP-dependent; SAMS, the synthetic peptide substrate with the amino acid sequence HMRSAMSGLHLVKRR; Bt2cAMP, dibutyryl cyclic AMP; ZMP, 5-amino-4-imidazolecarboxamide ribotide.

    REFERENCES
Top
Abstract
Introduction
Procedures
Results & Discussion
References

  1. Girard, J., Ferré, P., and Foufelle, F. (1997) Annu. Rev Nutr. 17, 325-352[CrossRef][Medline] [Order article via Infotrieve]
  2. Towle, H. C., Kaytor, E. N., and Shih, H. M. (1997) Annu. Rev. Nutr. 17, 405-433[CrossRef][Medline] [Order article via Infotrieve]
  3. Foufelle, F., Gouhot, B., Pégorier, J. P., Perdereau, D., Girard, J., and Ferré, P. (1992) J. Biol. Chem. 267, 20543-20546[Abstract/Free Full Text]
  4. Doiron, B., Cuif, M.-H., Kahn, A., and Diaz-Guerra, M. J. (1994) J. Biol. Chem. 269, 10213-10216[Abstract/Free Full Text]
  5. Prip-Buus, C., Perdereau, D., Foufelle, F., Maury, J., Ferré, P., and Girard, J. (1995) Eur. J. Biochem. 230, 309-315[Abstract]
  6. Mourrieras, F., Foufelle, F., Foretz, M., Morin, J., Bouché, S., and Ferré, P. (1997) Biochem. J. 326, 345-349[Medline] [Order article via Infotrieve]
  7. Doiron, B., Cuif, M. H., Chen, R., and Kahn, A. (1996) J. Biol. Chem. 271, 5321-5324[Abstract/Free Full Text]
  8. Jackson, S. P. (1992) Trends Cell. Biol. 2, 104-108[CrossRef]
  9. Sudo, Y., and Mariash, C. N. (1994) Endocrinology 134, 2532-2540[Abstract]
  10. Berry, M. N., and Friend, D. S. (1969) J. Cell. Biol. 43, 506-520[Abstract/Free Full Text]
  11. Spence, J. T., and Pitot, H. C. (1980) J. Cell. Physiol. 103, 173-178[Medline] [Order article via Infotrieve]
  12. Narkewicz, M. R., Ferré, P., Iynedjian, P. B., and Girard, J. (1990) Biochem. J. 271, 585-589[Medline] [Order article via Infotrieve]
  13. Ferré, P., Pégorier, J. P., Williamson, D. H., and Girard, J. (1979) Biochem. J. 182, 593-598[Medline] [Order article via Infotrieve]
  14. Sullivan, J. E., Carey, F., Carling, D., and Beri, R. K. (1994) Biochem. Biophys. Res. Commun. 200, 1551-1556[CrossRef][Medline] [Order article via Infotrieve]
  15. Carling, D., Clarke, P. R., Zammit, V. A., and Hardie, D. G. (1989) Eur. J. Biochem. 186, 129-136[Abstract]
  16. Chomczynski, P., and Sacchi, N. (1987) Anal. Biochem. 162, 156-159[CrossRef][Medline] [Order article via Infotrieve]
  17. Coupé, C., Perdereau, D., Ferré, P., Hitier, Y., Narkewicz, M., and Girard, J. (1990) Am. J. Physiol. 258, E126-E133[Abstract/Free Full Text]
  18. Dugail, I., Quignard-Boulangé, A., Le Liepvre, X., Ardouin, B., and Lavau, M. (1992) Biochem. J. 281, 607-611[Medline] [Order article via Infotrieve]
  19. Bialojan, C., and Takai, A. (1988) Biochem. J. 256, 283-290[Medline] [Order article via Infotrieve]
  20. Haystead, T. A. J., Sim, A. T. R., Carling, D., Honnor, R. C., Tsukitani, Y., Cohen, P., and Hardie, D. G. (1989) Nature 337, 78-81[CrossRef][Medline] [Order article via Infotrieve]
  21. O'Brien, R. M., Noisin, E. L., and Granner, D. K. (1994) Biochem. J. 303, 737-742[Medline] [Order article via Infotrieve]
  22. Hardie, D. G. (1993) in Protein Phosphorylation, A Practical Approach (Rickwood, D., and Hames, B. D., eds), pp. 87-107, Oxford University Press, Oxford
  23. Garrison, J. C., Johnsen, D. E., and Campanile, C. P. (1984) J. Biol. Chem. 259, 3283-3292[Abstract/Free Full Text]
  24. Tokumitsu, H., Chijiwa, T., Hagiwara, M., Mizutani, A., Terasawa, M., and Hidaka, H. (1990) J. Biol. Chem. 265, 4315-4320[Abstract/Free Full Text]
  25. Corton, J. M., Gillespie, J. G., Hawley, S. A., and Hardie, D. G. (1995) Eur. J. Biochem. 229, 558-565[Abstract]
  26. Foufelle, F., Gouhot, B., Perdereau, D., Girard, J., and Ferré, P. (1994) Eur. J. Biochem. 223, 893-900[Abstract]
  27. Kinlaw, W. B., Schwartz, H. L., Towle, H. C., and Oppenheimer, J. H. (1986) J. Clin. Invest. 78, 1091-1096[Medline] [Order article via Infotrieve]
  28. Decaux, J. F., Antoine, B., and Kahn, A. (1989) J. Biol. Chem. 264, 11584-11590[Abstract/Free Full Text]
  29. Lefrançois-Martinez, A. M., Diaz-Guerra, M. J., Vallet, V., Kahn, A., and Antoine, B. (1994) FASEB J. 8, 89-96[Abstract/Free Full Text]
  30. Rangan, V. S., Oskouian, B., and Smith, S. (1996) J. Biol. Chem. 271, 2307-2312[Abstract/Free Full Text]
  31. Sullivan, J. E., Brocklehurst, K. J., Marley, A. E., Carey, F., Carling, D., and Beri, R. K. (1994) FEBS Lett. 353, 33-36[CrossRef][Medline] [Order article via Infotrieve]
  32. Iynedjian, P. B., Jotterand, D., Nouspikel, T., Asfari, M., and Pilot, P. R. (1989) J. Biol. Chem. 264, 21824-21829[Abstract/Free Full Text]
  33. Carling, D., Zammit, V. A., and Hardie, D. G. (1987) FEBS Lett. 223, 217-222[CrossRef][Medline] [Order article via Infotrieve]
  34. Carling, D., Aguan, K., Woods, A., Verhoeven, A. J. M., Beri, R. K., Brennan, C. H., Sidebottom, C., Davison, M. D., and Scott, J. (1994) J. Biol. Chem. 269, 11442-11448[Abstract/Free Full Text]
  35. Woods, A., Munday, M. R., Scott, J., Yang, X., Carlson, M., and Carling, D. (1994) J. Biol. Chem. 269, 19509-19515[Abstract/Free Full Text]
  36. Carling, D., Aguan, K., Woods, A., Verhoeven, A. J. M., Beri, R. K., Brennan, C. H., Sidebottom, C., Davison, M. D., and Scott, J. (1994) J. Biol. Chem. 269, 11442-11448[Abstract/Free Full Text]
  37. Woods, A., Cheung, P. C. F., Smith, F. C., Davison, M. D., Scott, J., Beri, R. K., and Carling, D. (1996) J. Biol. Chem. 271, 10282-10290[Abstract/Free Full Text]
  38. Dyck, J. R. B., Gao, G., Widmer, J., Stapleton, D., Fernandez, C. S., Kemp, B. E., and Witters, L. A. (1996) J. Biol. Chem. 271, 17798-17803[Abstract/Free Full Text]
  39. Celenza, J. L., and Carlson, M. (1986) Science 233, 1175-1180[Medline] [Order article via Infotrieve]
  40. DeVit, M. J., Waddle, J. A., and Johnston, M. (1997) Mol. Biol. Cell 8, 1603-1618[Abstract]
  41. Gancedo, J. M. (1992) Eur. J. Biochem. 206, 297-313[Medline] [Order article via Infotrieve]
  42. Davies, S. P., Helps, N. R., Cohen, P. T. W., and Hardie, D. G. (1995) FEBS Lett. 377, 421-425[CrossRef][Medline] [Order article via Infotrieve]
  43. Lin, K., Rath, V. L., Dai, S. C., Fletterick, R. J., and Hwang, P. K. (1996) Science 273, 1539-1541[Abstract]
  44. Cadefau, J., Bollen, M., and Stalmans, W. (1997) Biochem. J. 322, 745-750[Medline] [Order article via Infotrieve]
  45. Lalli, E., and Sassone-Corsi, P. (1994) J. Biol. Chem. 269, 17359-17362[Free Full Text]


Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.